Quality of cancer care

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1001-1006

  Vardy, J ^a   Tannock, I F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer care; Evidence based medicine; Quality of treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CENTER; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; FATIGUE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; INTERPERSONAL COMMUNICATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; METHODOLOGY; OUTCOMES RESEARCH; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT REFERRAL; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PATIENT CARE; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 4143118986     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh275     Document Type: Review

References (55)

1. Talcott JA. Quality of care in prostate cancer: important to start and too important to stop here. J Clin Oncol 2003; 21: 1902-1903.
2. Feinstein AR. Fraud, distortion, delusion, and consensus: the problems of human and natural deception in epidemiologic science. Am J Med 1988; 84: 475-478.
3. Krzyzanowska MK, Pintilie M, Brezden-Masley C et al. The quality of abstracts describing randomized trials in the Proceedings of ASCO meetings; guidelines for improved reporting. J Clin Oncol 2004; In press.
4. Tannock IF. False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. J Natl Cancer Inst 1996; 89: 206-207.
5. Mills JL. Data torturing. N Engl J Med 1993; 329: 1196-1199.
6. Chlebowski RT, Lillington LM. A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol 1994; 12: 1789-1795.
7. Parmar MK, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst 1996; 88: 1645-1651.
8. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 1999; 79: 538-544.
9. Fayers PM, Hopwood P, Harvey A et al. Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer 1997; 33: 20-28.
10. Hayward RS, Wilson MC, Tunis SR et al. Users' guides to the medical literature VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. JAMA 1995; 274: 570-574.
11. Girling DJ. Clinical Trials in Cancer: Principles and Practice. New York: Oxford University Press 2003.
12. Begg C, Cho M, Eastwood S et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276: 637-639.
13. Altman DG, Schulz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
14. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 2002; 287: 2801-2804.
15. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003; 290: 495-501.
16. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17.
17. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867.
18. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425-431.
19. Messing EM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-1222.
20. Porzsolt F. Adjuvant therapy of renal cell cancer (RCC) with interferon alfa-2A. Proc Am Soc Clin Oncol 1992; 11: 202 (Abstr 622).
21. Smith TJ, Hillner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 2001; 19: 2886-2897.
22. Browman GP, Levine MN, Mohide EA et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995; 13: 502-512.
23. Ray-Coquard I, Philip T, de Laroche G et al. A controlled before-after study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer 2002; 86: 313-321.
24. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000; 18: 2327-2340.
25. Glasgow RE, Mulvihill SJ. Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996; 165: 294-300.
26. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222: 638-645.
27. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-1751.
28. Hodgson DC, Zhang W, Zaslavsky AM et al. Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst 2003; 95: 708-716.
29. Davis S, Dahlberg S, Myers MH et al. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance. Epidemiology, and End Results Program. J Natl Cancer Inst 1987; 78: 471-478.
30. Feuer EJ, Frey CM, Brawley OW et al. After a treatment break-through: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994; 12: 368-377.
31. Horowitz MM, Przepiorka D, Champlin RE et al. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood 1992; 79: 2771-2774.
32. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363-370.
33. Twelves CJ, Thomson CS, Gould A, Dewar JA. Variation in the survival of women with breast cancer in Scotland. The Scottish Breast Cancer Focus Group and The Scottish Cancer Therapy Network. Br J Cancer 1998; 78: 566-571.
34. Campbell NC, Elliott AM, Sharp L et al. Rural factors and survival from cancer: analysis of Scottish cancer registrations. Br J Cancer 2000; 82: 1863-1866.
35. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 1993; 341: 999-1002.
36. Collette L, Sylvester RJ, Stenning SP et al. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999; 91: 839-846.
37. Aass N, Klepp O, Cavallin-Stahl E et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991; 9: 818-826.
38. Davis S, Wright PW, Schulman SF et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56: 1710-1718.
39. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989; 299: 1069-1072.
40. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91: 2246-2257.
41. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 263-270.
42. Tannock IF. Treating the patient, not just the cancer. N Engl J Med 1987; 317: 1534-1535.
43. Fortner BV, Okon TA, Ashley J et al. The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage 2003; 25: 334-343.
44. de Wit R, van Dam F, Loonstra S et al. Improving the quality of pain treatment by a tailored pain education programme for cancer patients in chronic pain. Eur J Pain 2001; 5: 241-256.
45. Stone P, Richardson A, Ream E et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11: 971-975.
46. Manzullo EF, Escalante CP. Research into fatigue. Hematol Oncol Clin North Am 2002; 16: 619-628.
47. Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer 2001; 92 (Suppl 6): 1689-1693.
48. Dimeo FC, Stieglitz RD, Novelli-Fischer U et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999; 85: 2273-2277.
49. Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Pract 2000; 8: 16-24.
50. Bruera E, Driver L, Barnes EA et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21: 4439-4443.
51. Fallowfield L, Jenkins V. Effective communication skills are the key to good cancer care. Eur J Cancer 1999; 35: 1592-1597.
52. Ellis PM, Tattersall MH. How should doctors communicate the diagnosis of cancer to patients? Ann Med 1999; 31: 336-341.
53. Fallowfield L, Jenkins V, Farewell V et al. Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet 2002; 359: 650-656.
54. Baile WF, Lenzi R, Kudelka AP et al. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 1997; 12: 166-173.
55. Jenkins V, Fallowfield L. Can communication skills training alter physicians' beliefs and behavior in clinics? J Clin Oncol 2002; 20: 765-769.